{"groups":[{"description":"Cetuximab loading dose of 400 milligrams/square meter (mg/m²) administered intravenously on Day 1 of Cycle 1; subsequently 250 mg/m² intravenously weekly.\n\nPemetrexed 500 mg/m² administered intravenously on Day 1 of every 21-day cycle, 1 hour after cetuximab.\n\nCarboplatin area under curve (AUC) 5 or cisplatin 75 mg/m² administered intravenously on Day 1 of every 21-day cycle, 30 minutes after pemetrexed.\n\nMaximum 6 cycles. Participants who did not experience disease progression after 6 cycles continued on cetuximab (250 mg/m² intravenously weekly) monotherapy until disease progression.","id":"FG000","title":"Cetuximab + Pemetrexed + Carboplatin/Cisplatin"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"}],"type":"Protocol Violation"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"69"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"69"}],"type":"Received ≥1 Dose of Any Study Drug"},{"achievements":[{"groupId":"FG000","numSubjects":"69"}],"type":"Completed 6 Cycles"},{"achievements":[{"comment":"All treated participants excluding those from a noncompliant study site.","groupId":"FG000","numSubjects":"58"}],"type":"Efficacy Population"},{"achievements":[{"groupId":"FG000","numSubjects":"63"}],"type":"Received Carboplatin"},{"achievements":[{"groupId":"FG000","numSubjects":"67"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}